Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
Purpose - A prospective phase II study was conducted to evaluate the efficacy of dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) as salvage chemotherapy for patients with Hodgkin's disease. - Patients and Methods - Fifty-five patients progressing on or relapsing afte...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 01, 1994
|
| In: |
Journal of clinical oncology
Year: 1994, Volume: 12, Issue: 3, Pages: 580-586 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.1994.12.3.580 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.1994.12.3.580 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.1994.12.3.580 
|
| Author Notes: | Michael G. Pfreundschuh, Ulrich Rueffer, Bernd Lathan, Norbert Schmitz, Oana Brosteanu, Dirk Hasenclever, Rainer Haas, Hartmut Kirchner, Peter Koch, Rolf Kuse, Markus Loeffler, and Volker Diehl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1925762602 | ||
| 003 | DE-627 | ||
| 005 | 20250717014101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250515s1994 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.1994.12.3.580 |2 doi | |
| 035 | |a (DE-627)1925762602 | ||
| 035 | |a (DE-599)KXP1925762602 | ||
| 035 | |a (OCoLC)1528045443 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pfreundschuh, Michael |d 1949-2018 |e VerfasserIn |0 (DE-588)108615871 |0 (DE-627)394701879 |0 (DE-576)289617227 |4 aut | |
| 245 | 1 | 0 | |a Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens |b a trial of the German Hodgkin's Disease Study Group. |c Michael G. Pfreundschuh, Ulrich Rueffer, Bernd Lathan, Norbert Schmitz, Oana Brosteanu, Dirk Hasenclever, Rainer Haas, Hartmut Kirchner, Peter Koch, Rolf Kuse, Markus Loeffler, and Volker Diehl |
| 264 | 1 | |c March 01, 1994 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druck-Ausgabe 21. September 2016 | ||
| 500 | |a Gesehen am 15.05.2025 | ||
| 520 | |a Purpose - A prospective phase II study was conducted to evaluate the efficacy of dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) as salvage chemotherapy for patients with Hodgkin's disease. - Patients and Methods - Fifty-five patients progressing on or relapsing after eight- or 10-drug chemotherapy (cyclophosphamide, vincristine, procarbazine, and prednisone plus doxorubicin, bleomycin, vinblastine, and dacarbazine [COPP+ABVD] or COPP+ABV+ifosfamide, methotrexate, etoposide, and prednisone [IMEP]) were treated with Dexa-BEAM. Patients who responded after two cycles of Dexa-BEAM either continued treatment for another two to three cycles or received high-dose chemotherapy/autologous bone marrow transplantation (HDCT/ABMT) with cyclophosphamide, etoposide, and carmustine (BCNU) (CVB) as conditioning regimen. - Results - Seventeen patients (31%) achieved a complete remission and 16 (29%) a partial remission, resulting in a response rate of 60% (95% confidence interval, 46% to 73%). Progressive disease developed in 18 patients. Toxicity of Dexa-BEAM was acceptable with pronounced, but temporary World Health Organization (WHO) grade III/IV granulocytopenia and thrombocytopenia occurring in more than 90% of all courses. Two patients died of sepsis during granulocytopenia. Three prognostic subgroups could be distinguished: (1) patients progressing on initial chemotherapy, (2) patients relapsing within 12 months, and (3) patients with late relapses. The response rates for these groups were 52%, 60%, and 83%, and the median survival duration 12, 29, and 40+ months, respectively. In a nonrandomized comparison, the survival of patients who responded to two cycles of Dexa-BEAM and had additional cycles of Dexa-BEAM (n = 14) was not different from those responding patients who underwent HDCT/ABMT (n = 19). However, the power to detect a 20% survival difference was only 33% in this comparison. - Conclusion - Dexa-BEAM is an effective salvage treatment for patients with Hodgkin's disease who fail to respond to multidrug chemotherapy. Efficacy and toxicity are comparable to HDCT/ABMT and underline the need for prospective randomized trials to define better the role of HDCT with and without ABMT in these patients. | ||
| 700 | 1 | |a Rueffer, U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lathan, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmitz, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brosteanu, O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hasenclever, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haas, Rainer |d 1955- |e VerfasserIn |0 (DE-588)173773524 |0 (DE-627)698678141 |0 (DE-576)134613805 |4 aut | |
| 700 | 1 | |a Kirchner, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koch, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuse, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loeffler, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Diehl, Volker |d 1938- |e VerfasserIn |0 (DE-588)120716437 |0 (DE-627)080847609 |0 (DE-576)160732212 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 12(1994), 3, Seite 580-586 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens a trial of the German Hodgkin's Disease Study Group. |
| 773 | 1 | 8 | |g volume:12 |g year:1994 |g number:3 |g pages:580-586 |g extent:7 |a Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens a trial of the German Hodgkin's Disease Study Group. |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.1994.12.3.580 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.1994.12.3.580 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250515 | ||
| 993 | |a Article | ||
| 994 | |a 1994 | ||
| 998 | |g 173773524 |a Haas, Rainer |m 173773524:Haas, Rainer |d 910000 |d 910100 |e 910000PH173773524 |e 910100PH173773524 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1925762602 |e 4724746483 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Elektronische Reproduktion der Druck-Ausgabe 21. September 2016","Gesehen am 15.05.2025"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1925762602","person":[{"given":"Michael","family":"Pfreundschuh","role":"aut","roleDisplay":"VerfasserIn","display":"Pfreundschuh, Michael"},{"roleDisplay":"VerfasserIn","display":"Rueffer, U.","role":"aut","family":"Rueffer","given":"U."},{"roleDisplay":"VerfasserIn","display":"Lathan, B.","role":"aut","family":"Lathan","given":"B."},{"given":"N.","family":"Schmitz","role":"aut","roleDisplay":"VerfasserIn","display":"Schmitz, N."},{"roleDisplay":"VerfasserIn","display":"Brosteanu, O.","role":"aut","family":"Brosteanu","given":"O."},{"given":"D.","family":"Hasenclever","role":"aut","display":"Hasenclever, D.","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Haas, Rainer","given":"Rainer","family":"Haas"},{"family":"Kirchner","given":"H.","display":"Kirchner, H.","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Koch, P.","roleDisplay":"VerfasserIn","role":"aut","family":"Koch","given":"P."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Kuse, R.","given":"R.","family":"Kuse"},{"family":"Loeffler","given":"Markus","roleDisplay":"VerfasserIn","display":"Loeffler, Markus","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Diehl, Volker","role":"aut","family":"Diehl","given":"Volker"}],"title":[{"title_sort":"Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens","title":"Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens","subtitle":"a trial of the German Hodgkin's Disease Study Group."}],"physDesc":[{"extent":"7 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"pubHistory":["1.1983 -"],"part":{"pages":"580-586","issue":"3","year":"1994","extent":"7","text":"12(1994), 3, Seite 580-586","volume":"12"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"disp":"Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens a trial of the German Hodgkin's Disease Study Group.Journal of clinical oncology","note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"role":"isb","display":"American Society of Clinical Oncology","roleDisplay":"Herausgebendes Organ"}],"language":["eng"],"recId":"313116962","title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}]}],"name":{"displayForm":["Michael G. Pfreundschuh, Ulrich Rueffer, Bernd Lathan, Norbert Schmitz, Oana Brosteanu, Dirk Hasenclever, Rainer Haas, Hartmut Kirchner, Peter Koch, Rolf Kuse, Markus Loeffler, and Volker Diehl"]},"origin":[{"dateIssuedKey":"1994","dateIssuedDisp":"March 01, 1994"}],"id":{"eki":["1925762602"],"doi":["10.1200/JCO.1994.12.3.580"]}} | ||
| SRT | |a PFREUNDSCHDEXABEAMIN0119 | ||